The PALTAN study is a phase II neoadjuvant trial of palbociclib in combination with letrozole and trastuzumab in early ER+HER2+ breast cancer, which commenced June 2017 (NCT02907918). This evidence concerns the gene ERBB2 and breast carcinoma.